|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mayer EL and Burstein HJ: Chemotherapy for
metastatic breast cancer. Hematol Oncol Clin North Am. 21:257–272.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Breast cancer, version 4.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
16:310–320. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneider BP and Miller KD: Angiogenesis
of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fox SB, Generali DG and Harris AL: Breast
tumour angiogenesis. Breast Cancer Res. 9:2162007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banerjee S, Dowsett M, Ashworth A and
Martin LA: Mechanisms of disease: Angiogenesis and the management
of breast cancer. Nat Clin Pract Oncol. 4:536–550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Willett CG, Boucher Y, di Tomaso E, Duda
DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et
al: Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bianchi G, Loibl S, Zamagni C, Salvagni S,
Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L and
Gianni L: Phase II multicenter, uncontrolled trial of sorafenib in
patients with metastatic breast cancer. Anticancer Drugs.
20:616–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moreno-Aspitia A, Morton RF, Hillman DW,
Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR and
Perez EA: Phase II trial of sorafenib in patients with metastatic
breast cancer previously exposed to anthracyclines or taxanes:
North central cancer treatment group and mayo clinic trial N0336. J
Clin Oncol. 27:11–15. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burstein HJ, Elias AD, Rugo HS, Cobleigh
MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo
SE, et al: Phase II study of sunitinib malate, an oral
multitargeted tyrosine kinase inhibitor, in patients with
metastatic breast cancer previously treated with an anthracycline
and a taxane. J Clin Oncol. 26:1810–1816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yardley DA, Dees EC, Myers SD, Li S,
Healey P, Wang Z, Brickman MJ, Paolini J, Kern KA and Citrin DL:
Phase II open-label study of sunitinib in patients with advanced
breast cancer. Breast Cancer Res Treat. 136:759–767. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wildiers H, Fontaine C, Vuylsteke P,
Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P
and Paridaens R: Multicenter phase II randomized trial evaluating
antiangiogenic therapy with sunitinib as consolidation after
objective response to taxane chemotherapy in women with
HER2-negative metastatic breast cancer. Breast Cancer Res Treat.
123:463–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barrios CH, Liu MC, Lee SC, Vanlemmens L,
Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, et
al: Phase III randomized trial of sunitinib versus capecitabine in
patients with previously treated HER2-negative advanced breast
cancer. Breast Cancer Res Treat. 121:121–131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mariani G, Burdaeva O, Roman L,
Staroslawska E, Udovitsa D, Driol P, Goisis G, Zamagni C,
Semiglazov V and Gianni L: A double-blind, randomized phase lib
study evaluating the efficacy and safety of sorafenib (SOR)
compared to placebo (PL) when administered in combination with
docetaxel and/or letrozole in patients with metastatic breast
cancer (MBC): FM-B07-01 Trial. Eur J Cancer. 47:102011. View Article : Google Scholar
|
|
17
|
Hudis C, Tauer KW, Hermann RC,
Makari-Judson G, Isaacs C, Beck JT, Kaklamani VG, Stepanski EJ,
Rugo HS, Wang W, et al: Sorafenib (SOR) plus chemotherapy (CRx) for
patients (pts) with advanced (adv) breast cancer (BC) previously
treated with bevacizumab (BEV). J Clin Oncol. 29:1009. 2011.
View Article : Google Scholar
|
|
18
|
Gradishar WJ, Kaklamani V, Sahoo TP,
Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA and
Schwartzberg L: A double-blind, randomised, placebo-controlled,
phase 2b study evaluating sorafenib in combination with paclitaxel
as a first-line therapy in patients with HER2-negative advanced
breast cancer. Eur J Cancer. 49:312–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baselga J, Segalla JG, Roché H, Del Giglio
A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B,
Bermejo B, et al: Sorafenib in combination with capecitabine: An
oral regimen for patients with HER2-negative locally advanced or
metastatic breast cancer. J Clin Oncol. 30:1484–1491. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aalders KC, Tryfonidis K, Senkus E and
Cardoso F: Anti-angiogenic treatment in breast cancer: Facts,
successes, failures and future perspectives. Cancer Treat Rev.
53:98–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Zhao X, Chen L, Guo H, Lv F, Jia K,
Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies. BMC
Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L,
Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of
apatinib in non-triple-negative metastatic breast cancer. BMC
Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
U.S.Department of Health, Human Services,
National Institutes of Health and National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE). Version 4.03.
https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdJune
14–2010
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carninci P, Kasukawa T, Katayama S, Gough
J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al:
The transcriptional landscape of the mammalian genome. Science.
309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerard T: Eastern Cooperative Oncology
Group Performance Status. Chemotherapy. 5:102012.
|
|
28
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu J, Liu X, Yang S, Zhang X and Shi Y:
Apatinib plus icotinib in treating advanced non-small cell lung
cancer after icotinib treatment failure: A retrospective study.
Onco Targets Ther. 10:4989–4995. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin Y, Wang C, Gao W, Cui R and Liang J:
Overwhelming rapid metabolic and structural response to apatinib in
radioiodine refractory differentiated thyroid cancer. Oncotarget.
8:42252–42261. 2017.PubMed/NCBI
|
|
31
|
Liu L, Yu H, Huang L, Shao F, Bai J, Lou D
and Chen F: Progression-free survival as a surrogate endpoint for
overall survival in patients with third-line or later-line
chemotherapy for advanced gastric cancer. Onco Targets Ther.
8:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang L, Wei Y, Shen S, Shi Q, Bai J, Li
J, Qin S, Yu H and Chen F: Therapeutic effect of apatinib on
overall survival is mediated by prolonged progression-free survival
in advanced gastric cancer patients. Oncotarget. 8:29346–29354.
2017.PubMed/NCBI
|
|
33
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al: Eribulin monotherapy versus treatment of
physician's choice in patients with metastatic breast cancer
(EMBRACE): A phase 3 open-label randomised study. Lancet.
377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blum JL, Jones SE, Buzdar AU, LoRusso PM,
Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T:
Multicenter phase II study of capecitabine in paclitaxel-refractory
metastatic breast cancer. J Clin Oncol. 17:485–493. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jehn CF, Hemmati P, Lehenbauer-Dehm S,
Kümmel S, Flath B and Schmid P: Biweekly pegylated liposomal
doxorubicin (caelyx) in heavily pretreated metastatic breast
cancer: A phase 2 study. Clin Breast Cancer. 16:514–519. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tong XZ, Wang F, Liang S, Zhang X, He JH,
Chen XG, Liang YJ, Mi YJ, To KK and Fu LW: Apatinib (YN968D1)
enhances the efficacy of conventional chemotherapeutical drugs in
side population cells and ABCB1-overexpressing leukemia cells.
Biochem Pharmacol. 83:586–597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu J, Li X, Xie C, Li Y and Zhong G:
Apatinib, a new small molecular VEGFR2 inhibitor, suppresses the
activity of lung cancer stem cells. J Thorac Oncol. 12 (Suppl
1):S12792017. View Article : Google Scholar
|
|
39
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai
Y, Wang Z, Yang Y, Sun G, Wang L, et al: Early presence of
anti-angiogenesis-related adverse events as a potential biomarker
of antitumor efficacy in metastatic gastric cancer patients treated
with apatinib: A cohort study. J Hematol Oncol. 10:1532017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fan M, Zhang J, Wang Z, Wang B, Zhang Q,
Zheng C, Li T, Ni C, Wu Z, Shao Z and Hu X: Phosphorylated VEGFR2
and hypertension: Potential biomarkers to indicate VEGF-dependency
of advanced breast cancer in anti-angiogenic therapy. Breast Cancer
Res Treat. 143:141–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
